or Try an Advanced Search...

    Precision Medicine Stocks List

    Symbol Grade Name % Change
    CRSP F CRISPR Therapeutics AG 1.49
    RLAY F Relay Therapeutics, Inc. -0.56
    EXAI F Exscientia Limited -8.25
    NTLA F Intellia Therapeutics, Inc. 1.42
    POAI F Predictive Oncology Inc. 6.47
    RPTX F Repare Therapeutics Inc. 2.99
    BIOR F Biora Therapeutics, Inc. 2.55
    View As Page of Charts
    Related Industries: Biotechnology Diagnostics & Research Health Information Services Medical Instruments & Supplies
    Related Stock Lists: Medicine Biology Cancer Biotechnology CRISPR Genetics Oncology Artificial Intelligence Biomarkers Biopharmaceutical Cancer Therapies Cas9 Clinical Medicine Disease Enzymes Genome Editing Genomics Immune System Proteomics Solid Tumors

    Related ETFs - A few ETFs which own one or more of the above listed Precision Medicine stocks.

    Symbol Grade Name Weight
    ARKG D ARK Genomic Revolution Multi-Sector ETF 11.44
    GNOM D Global X Genomics & Biotechnology ETF 8.14
    ARKK D ARK Innovation ETF 7.0
    NXTE C AXS Green Alpha ETF 4.97
    MEDX F Horizon Kinetics Medical ETF 4.06
    View all Precision Medicine ETFs...
    Compare ETFs
    Compare ARKG to MEDX Compare GNOM to NXTE Compare NXTE to MEDX

        Precision Medicine Stocks Recent News

        Date Stock Title
        May 3 NTLA Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
        May 3 CRSP CRISPR Therapeutics AG (CRSP) Outperforms Broader Market: What You Need to Know
        May 3 CRSP Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
        May 3 NTLA IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
        May 3 RLAY Relay Therapeutics GAAP EPS of -$0.62 beats by $0.10, revenue of $10.01M beats by $9.09M
        May 2 RLAY Relay Therapeutics Outperforms Revenue Expectations in Q1 2024
        May 2 RLAY Relay Therapeutics, Inc. (RLAY) Reports Q1 Loss, Tops Revenue Estimates
        May 2 RLAY Relay Therapeutics GAAP EPS of -$0.62 beats by $0.08, revenue of $10M beats by $9.89M
        May 2 RLAY Relay Therapeutics Reports First Quarter 2024 Financial Results and Corporate Highlights
        May 2 NTLA Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
        May 2 CRSP 3 Biotech Stocks to Buy and Hold Through 2030 and Beyond
        May 1 CRSP Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock
        Apr 30 POAI Predictive Oncology stock rallies 30% post-market on vaccine collaboration
        Apr 30 POAI Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
        Apr 30 CRSP Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
        Apr 30 BIOR Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
        Apr 30 RPTX Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition
        Apr 30 RPTX Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition
        Apr 29 EXAI Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
        Apr 29 NTLA Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024
        Related Industries: Biotechnology Diagnostics & Research Health Information Services Medical Instruments & Supplies
        Related Stock Lists: Biology Biotechnology Medicine Systems Biology Cancer Disease Immune System Biomarkers CRISPR Cancer Treatment Cas9 Checkpoint Inhibitor Clinical Development Evidence Based Medicine Genetics Genome Editing Molecular Biology Oncology Solid Tumors Targeted Therapy
        Precision Medicine

        Precision medicine (PM) is a medical model that proposes the customization of healthcare, with medical decisions, treatments, practices, or products being tailored to the individual patient, instead of a one‐drug‐fits‐all model. In precision medicine, diagnostic testing is often employed for selecting appropriate and optimal therapies based on the context of a patient’s genetic content or other molecular or cellular analysis. Tools employed in precision medicine can include molecular diagnostics, imaging, and analytics.

        More about Precision Medicine
        Browse All Tags